Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Geron Restructuring Sours Investors As Company Bets On Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.

You may also be interested in...



Geron CEO: Getting Imetelstat Data Wanted By FDA Will Be “Difficult”

Concerned about chronic liver injury, FDA halts development of Geron’s telomerase inhibitor imetelstat, the only drug left standing in Geron’s pipeline, and requests data for patients who discontinued treatment in Geron-sponsored plus non-Geron studies.

For Cutting-Edge Stem Cell Work, California Billions Still Unmatched

California’s stem cell agency still has nearly two billion dollars to grant. But with recent stem cell breakthroughs slow to translate, will venture backers and drug firms help build the ecosystem California citizens imagined in 2004 when they voted to make the state a beacon for the science?

Mesoblast Advances Stem-Cell Drugs As Catalysts Approach

Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel